FARN:LON
Faron Pharmaceuticals Oy
36,75 GBX
arrow_upward
+0,68%(+0,25) 1 D
9. okt., 08:41:11 GMT+1 · GBX
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for FARN …
Åpne
35,00 GBX
Høy
38,00 GBX
Lav
35,00 GBX
Markedsverdi
74,49 mill.
Snittvolum
45,22k
Volum
2,98k
52 u høy
193,58 GBX
52 u lav
34,00 GBX
EPS
−0,10 GBX
Utestående aksjer
31,03 mill.
Antall ansatte
36
Åpne
35,00 GBX
Høy
38,00 GBX
Lav
35,00 GBX
Markedsverdi
74,49 mill.
Snittvolum
45,22k
Volum
2,98k
52 u høy
193,58 GBX
52 u lav
34,00 GBX
EPS
−0,10 GBX
Utestående aksjer
31,03 mill.
Antall ansatte
36
Nyhetssaker
Fra nettkilder og nyhetspartnere
marketscreener.com
·
for 1 døgn siden
Faron agrees bond repayment deferrals for more financial flexibility
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Om Faron Pharmaceuticals Oy